MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY

摘要

Fc-engineered variants of anti-PD1 IgG antibodies that abrogate FcϒR binding and mAb effector functions, or combinations with therapies that inhibit FcϒR binding in vivo, for treatment of cancer.